Spinraza patent expiration?

When Does Spinraza Patent Expiration Occur?

Spinraza, also known as nusinersen, is a medication used to treat spinal muscular atrophy (SMA). Developed by Biogen, it has been a game-changer in the treatment of this condition, a genetic disorder that affects nerve cells responsible for movement.

How Long Does Biogen Have Exclusivity?

The Spinraza patent was approved in December 2016 [1]. According to the Patent and Trademark Office, Biogen's nusinersen composition patent is set to expire on November 27, 2028 [2]. This means that generic competitors will be able to enter the market before the end of the next decade, assuming no further patent extensions are granted.

Can Biosimilars Enter Before Patent Expiry?

While patent expiration marks the end of exclusivity, biosimilar developers must still go through a thorough approval process, which includes demonstrating safety and efficacy. Biogen has a patent on the drug's manufacturing process, which could potentially slow the entry of generic competitors [3].

What Happens If... Generic Competitors Enter the Market Early?

In the event that the patent is challenged or a biosimilar is approved before the expiration date, it's likely that generic competitors will aggressively promote their products to doctors and patients, potentially increasing market competition.

What's Next for Biogen's Spinraza?

Biogen's spinraza patent expires in 2028, and while the company may attempt to extend its exclusivity, generic competition will likely become a significant factor in the market.

Sources:

[1] U.S. Food and Drug Administration. (2016). Nusinersen. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208620Orig1s000TOC.cfm

[2] United States Patent and Trademark Office. (2022). Patent Term Extension and Patent Term Adjustments. https://www.uspto.gov/patent-processes/patent-term-extension-patent-term-adjustments

[3] DrugPatentWatch.com. (2023). Nusinersen (Spinraza). https://www.drugpatentwatch.com/nusinersen-208620

References:

1. U.S. Food and Drug Administration. (2016). Nusinersen.
2. United States Patent and Trademark Office. (2022). Patent Term Extension and Patent Term Adjustments.
3. DrugPatentWatch.com. (2023). Nusinersen (Spinraza).